Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB Cause Epstein-barr virus infection? 575 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 575 reports of Epstein-barr virus infection have been filed in association with RITUXIMAB (Rituxan). This represents 0.3% of all adverse event reports for RITUXIMAB.

575
Reports of Epstein-barr virus infection with RITUXIMAB
0.3%
of all RITUXIMAB reports
233
Deaths
171
Hospitalizations

How Dangerous Is Epstein-barr virus infection From RITUXIMAB?

Of the 575 reports, 233 (40.5%) resulted in death, 171 (29.7%) required hospitalization, and 76 (13.2%) were considered life-threatening.

Is Epstein-barr virus infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB. However, 575 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB Cause?

Off label use (39,751) Drug ineffective (32,186) Rheumatoid arthritis (19,850) Pain (16,675) Fatigue (15,602) Arthralgia (12,529) Rash (12,102) Drug intolerance (11,876) Infusion related reaction (11,871) Joint swelling (11,170)

What Other Drugs Cause Epstein-barr virus infection?

TACROLIMUS (1,252) MYCOPHENOLATE MOFETIL (1,191) PREDNISONE (815) CYCLOSPORINE (793) METHOTREXATE (749) CYCLOPHOSPHAMIDE (629) PREDNISOLONE (592) FLUDARABINE (476) METHYLPREDNISOLONE (443) LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN (314)

Which RITUXIMAB Alternatives Have Lower Epstein-barr virus infection Risk?

RITUXIMAB vs RITUXIMAB-ABBS RITUXIMAB vs RITUXIMAB-ARRX RITUXIMAB vs RITUXIMAB-PVVR RITUXIMAB vs RIVAROXABAN RITUXIMAB vs RIVASTIGMINE

Related Pages

RITUXIMAB Full Profile All Epstein-barr virus infection Reports All Drugs Causing Epstein-barr virus infection RITUXIMAB Demographics